Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. (Q52856000)

8 May 2018

title

Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. (English)

1 reference

8 May 2018

main subject

phase II clinical trial

0 references

1 reference

1 reference

1 reference

8 May 2018

Məsud Aşina

object named as

Messoud Ashina

1 reference

8 May 2018

David W Dodick

1 reference

8 May 2018

Stephen D. Silberstein

object named as

Stephen Silberstein

1 reference

8 May 2018

Hong Sun

1 reference

8 May 2018

Uwe Reuter

1 reference

8 May 2018

Joel Saper

1 reference

8 May 2018

Roger Cady

1 reference

8 May 2018

Yun Chon

1 reference

8 May 2018

Julie Dietrich

1 reference

8 May 2018

Robert Lenz

1 reference

8 May 2018

publication date

12 February 2016

1 reference

8 May 2018

published in

Lancet Neurology

1 reference

8 May 2018

volume

1 reference

8 May 2018

issue

1 reference

8 May 2018

page(s)

382-390

1 reference

8 May 2018

Systematic review of migraine prophylaxis adherence and persistence

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

Migraine prevalence, disease burden, and the need for preventive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

Vasoactive peptide release in the extracerebral circulation of humans during migraine headache

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

Topiramate for migraine prevention: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

Localization of CGRP receptor components and receptor binding sites in rhesus monkey brainstem: A detailed study using in situ hybridization, immunofluorescence, and autoradiography

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

Opening of the blood-brain barrier preceding cortical edema in a severe attack of FHM type II

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

The role of the blood-brain barrier in the development and treatment of migraine and other pain disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

The blood-brain barrier in migraine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

A second trigeminal CGRP receptor: function and expression of the AMY1 receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

Drug safety and tolerability in prophylactic migraine treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

Adherence to oral migraine-preventive medications among patients with chronic migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

Topiramate in migraine prevention: results of a large controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

Calcitonin gene-related peptide: physiology and pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900019-3

7 January 2021

10.1016/S1474-4422(16)00019-3

Identifiers

DOI

1 reference

8 May 2018

release_4ed2vkzimfgrxb4fg75rlp5kpu

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4ed2vkzimfgrxb4fg75rlp5kpu

24 November 2022

mapped directly with Wikidata item

1 reference

8 May 2018